Citizens JMP initiated coverage of Quince Therapeutics (QNCX) with an Outperform rating and $9 price target The firm says Quince is using its Autologous Intracellular Drug Encapsulation platform to treat rare diseases using a patient’s own biology. The company’s lead candidate eDSP offers a blockbuster opportunity with limited competition, the analyst tells investors in a research note. Citizens believes pipeline expansion at Quince could move quickly and drive additional share upside.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics files to sell 6.67M shares of common stock for holders
- Quince Therapeutics Completes Enrollment for Phase 3 Trial
- Quince Therapeutics completes enrollment in NEAT clinical trial
- Quince Therapeutics initiated with a Buy at Lucid Capital
- Quince Therapeutics Raises $11.5M in Private Placement